| 1.28 0.24 (23.08%) | 11-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.64 | 1-year : | 2 |
| Resists | First : | 1.4 | Second : | 1.72 |
| Pivot price | 1.15 |
|||
| Supports | First : | 0.9 | Second : | 0.74 |
| MAs | MA(5) : | 1.12 | MA(20) : | 1.19 |
| MA(100) : | 1.63 |
MA(250) : | 2.55 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 43.2 |
D(3) : | 34.4 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 7.04 | Low : | 0.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DWTX ] has closed below upper band by 12.8%. Bollinger Bands are 45.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.07 - 1.07 | 1.07 - 1.08 |
| Close: | 1.27 - 1.28 | 1.28 - 1.29 |
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Fri, 06 Nov 2026
After a roughly $5M share sale, Dogwood Therapeutics (DWTX) expects to need more financing. - Stock Titan
Thu, 05 Nov 2026
Dogwood Therapeutics, Inc. (DWTX) stock price, news, quote and history - Yahoo Finance Singapore
Thu, 05 Nov 2026
Dogwood Therapeutics Announces Third Quarter 2026 Financial Results - Yahoo Finance
Fri, 30 Oct 2026
Stockholders Plan to Sell 4.1 Million Shares of Dogwood Therapeu - GuruFocus
Sat, 24 Oct 2026
Dogwood Therapeutics, Inc. Estimates – NASDAQ:DWTX - TradingView
Wed, 21 Oct 2026
A 4.1M-share sale by Dogwood Therapeutics (DWTX) is expected to close by October 29. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 72.5 (%) |
| Held by Institutions | 11.4 (%) |
| Shares Short | 39 (K) |
| Shares Short P.Month | 89 (K) |
| EPS | 2.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | -47.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | 0.58 |
| PEG Ratio | 0 |
| Price to Book value | 0.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|